Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
NRG Oncology
Insel Gruppe AG, University Hospital Bern
Fudan University
Sun Yat-sen University
Groupe Oncologie Radiotherapie Tete et Cou
Groupe Oncologie Radiotherapie Tete et Cou
National Cancer Institute (NCI)
Centre Leon Berard
Groupe Oncologie Radiotherapie Tete et Cou